Skip to content

FDA Adds an Optic Nerve Warning to Every GLP-1 Medicine Label: What Patients Should Know

  • by

On November 9, 2026, the U.S. Food and Drug Administration (FDA) announced that every GLP-1 receptor agonist medicine must add a warning about a rare eye condition to its label. These medicines are widely used for type 2 diabetes and for weight loss. If you take one, here is what the announcement says, in plain language.

The condition: NAION

NAION (non-arteritic anterior ischemic optic neuropathy) happens when blood flow to the front of the optic nerve drops. The FDA describes it as a rare condition that can cause sudden, painless loss of vision in one eye, sometimes permanently.

What the FDA found

  • In an analysis of 126 randomized clinical trials, NAION occurred at a rate of 6.4 cases per 100,000 person-years with GLP-1 medicines, compared with 3.8 per 100,000 person-years with placebo or other diabetes medicines. That was 15 probable cases in total.
  • In an FDA real-world study of adults with type 2 diabetes, risk was not significantly higher than with SGLT-2 inhibitors, but was higher than with DPP-4 inhibitors.
  • NAION has been reported with all currently marketed GLP-1 medicines, so the warning applies to the whole class.

Symptoms to watch for

The FDA lists sudden, painless vision loss in one eye, often noticed on waking; blurred or missing areas of vision; color distortion; and hazy spots in central vision. If you notice any of these, contact your prescriber and an eye doctor right away.

What to do if you take a GLP-1 medicine

  • Do not stop on your own. The benefits for blood sugar, weight and heart health are real, and the absolute risk remains low.
  • If you have had NAION before, tell your prescriber. The FDA notes that NAION in one eye raises the risk in the other eye, and patients who have had it should discuss whether to continue.
  • Keep regular dilated eye exams, especially if you have diabetes.

For eye health guides from cities around the country, browse this national eye health site.

My advice is simple: know the warning signs, keep your eye exams, and make any medication decision with your doctor, not out of fear.

Source: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition (U.S. Food and Drug Administration, Drug Safety Communication, 11/9/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.

Leave a Reply

Your email address will not be published. Required fields are marked *